Genflow Biosciences Plc ( (GB:GENF) ) has issued an update.
Genflow Biosciences Plc announced that its CEO, Dr. Eric Leire, has acquired 2,100,000 ordinary shares of the company, increasing his total shareholding to 36.18%. This purchase underscores the CEO’s confidence in the company’s strategic direction and its pioneering work in gene therapy for aging and chronic diseases, potentially strengthening its position in the biotechnology sector.
More about Genflow Biosciences Plc
Genflow Biosciences Plc, founded in 2020 and headquartered in the UK with R&D facilities in Belgium, is a biotechnology company specializing in gene therapies aimed at slowing the aging process. Their lead compound, GF-1002, targets the SIRT6 gene and is set to enter clinical trials in 2025 to potentially treat Metabolic Dysfunction-Associated Steatohepatitis (MASH), a prevalent chronic liver disease.
YTD Price Performance: -31.40%
Average Trading Volume: 1,275,652
Technical Sentiment Signal: Buy
Find detailed analytics on GENF stock on TipRanks’ Stock Analysis page.